Everolimus fails to extend life in advanced liver cancer Survival rates in patients with advanced liver cancer are not improved by the mTOR inhibitor everolimus, the EVOLVE-1 clinical trial suggests.…
Pinpointing a weakness in bacteria’s protective barrier An international team of scientists have identified how gram-negative bacteria build a protective barrier against antibiotics.…
Carbapenems have stood the test of time so far but resistance is emerging Jenny Bryan takes a look at the discovery of carbapenem antibiotics and their role as the last line of defence against drug-resistant Gram-negative bacteria.…
Thermotherapy and cryotherapy Hot and cold therapies are widely used to treat muscle pain and sports injuries. Help your patients choose the right treatment option with our essential guide…
Naloxegol effective in treating opioid-induced constipation Naloxegol has shown efficacy in two phase III clinical trials.…
Ever heard of Ehlers-Danlos syndrome?One in 5,000 people has Ehlers-Danlos syndrome — at least twice the number as have sickle cell anaemia, phenylketonuria or haemophilia A. Learn more about it here…
Simvastatin has no therapeutic benefit in COPD, researchers concludeSimvastatin does not prevent exacerbations in people with moderate-to-severe chronic obstructive pulmonary disease (COPD)…
“Hidden factors” behind antibiotics and asthma linkAnalysis of a long-term study suggests that the association between antibiotic use in infancy and an increased risk of developing asthma — or exacerbating an existing condition — may not be a simple causal link.…
Clinical research: see it, do it, lead itPavitar Gandham and colleagues at Guy’s and St Thomas’ NHS Foundation Trust explain what it is like to be some of the first pharmacists to become NIHR trainee research fellows…
How filgrastim has helped control neutropenia and prevent sepsisHow the granulocyte colony-stimulating factor filgrastim has become part of the staple diet of chemotherapy…
